Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
54 hedge funds and large institutions have $288M invested in Akero Therapeutics in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 17 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
41% more capital invested
Capital invested by funds: $205M → $288M (+$83.7M)
13% more funds holding
Funds holding: 48 → 54 (+6)
5.15% more ownership
Funds ownership: 39.46% → 44.62% (+5.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$29.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.97M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$7.55M |
| 4 |
Alkeon Capital Management
New York
|
+$6.56M |
| 5 |
BlackRock
New York
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.11M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.87M |
| 3 |
Millennium Management
New York
|
-$2.19M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.11M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.49M |
AKRO Hedge Fund Activity: Q3 2019 in Review
54 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2019, worth a combined $288M — up 41% from $205M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AKRO positions and 17 closed out — a net gain of 7 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $29.5M. The largest seller was BVF Inc, cutting an estimated $4.11M.
- 54 institutional investors held Akero Therapeutics (AKRO) as of Q3 2019, up from 48 in Q2 2019.
- Funds reported $288M of Akero Therapeutics stock for Q3 2019, up 41% quarter-over-quarter.
- 24 funds opened new Akero Therapeutics positions in Q3 2019 and 17 closed out, a net change of +7 holders.
- The largest Akero Therapeutics buyer in Q3 2019 was Janus Henderson Group, an estimated $29.5M added.
- The largest Akero Therapeutics seller in Q3 2019 was BVF Inc, an estimated $4.11M sold.
Based on aggregated 13F filings for Q3 2019.